Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

Active, not recruiting

• Conditions: Hematologic Malignancy; SARS-CoV-2 Infection
• Interventions: Other: None intervention

• Registration Number: NCT05683353
• Lead Sponsor: Peking University First Hospital

Brief Summary

The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.

Detailed Description

To establish a retrospective and prospective cohort of patients with hematologic tumors infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2. Firstly, peripheral blood samples will be collected at infection time points and after SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome sequencing and immunological experiments will be performed to analyze the differentially expressed genes, immune function of cells, etc.

Comparative analysis:

1. To compare the immune function of patients with hematologic tumors and those without underlying diseases after infection with SARS-CoV-2.

2. The transcriptomic and proteomic changes of patients with hematologic tumors are compared with those without underlying diseases after infection with SARS-CoV-2.

3. From the perspective of complex (human protein interaction subnetwork), the dynamic change process of SARS-CoV-2-targeted human protein complex (periodic complex) was deeply explored, in order to further analyze its potential dynamic infection mechanism and provide new clues for the discovery of drug targets.

Study Timeline

• Study Start: 2022-12-14
• Study First Submitted: 2023-01-04
• Study First Submitted QC: 2023-01-04
• Study First Posted: 2023-01-13
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-02
• Last Update Posted: 2024-04-04
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection

Exclusion Criteria

• Severe diseases associated with other systems

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with SARS-CoV-2 positive hematologic tumors	None intervention	Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems.
People with SARS-CoV-2 positive without underlying diseases	None intervention	People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems.

Primary Outcome Measures

Name	Time	Method
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors	1 year	To compare the infection mechanism and immune function of patients with hematologic tumors infected with SARS-CoV-2 and people infected with SARS-CoV-2 without underlying diseases.

Trial Locations

Locations (1)

Peking University First Hospital; 🇨🇳 Beijing, Beijing, China